Drug
Abivertinib clinical trials
Also written AC0010, AC0010MA and avitinib.
- studies test it
- 13
- open now
- 0
- in phase 3
- 2
- first study started
- 2014
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
13 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
Hangzhou ACEA Pharmaceutical Research Co., Ltd. (7) · Sorrento Therapeutics, Inc. (3) · ACEA Therapeutics, Inc. (1) · Guangdong Association of Clinical Trials (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Abiraterone (1) · Afatinib (1) · Crizotinib (1) · Ensartinib (1) · Tucidinostat (1) · Shr-1258 dimaleate (1) · AZD3759 (1) · Pirotinib (1)
Studies
Open first, then newest update. How each study uses abivertinib is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedPhase 2Sorrento Therapeutics, Inc.NCT05361915Written as Abivertinib
- Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedPhase 2Sorrento Therapeutics, Inc.NCT04440007Written as Abivertinib
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as Avitinib Maleate
- Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedPhase 2Sorrento Therapeutics, Inc.NCT04528667Written as STI-5656
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCStatus unknownPhase 1/2Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT02330367Written as AC0010
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung CancerTerminatedPhase 1ACEA Therapeutics, Inc.NCT02448251Written as AC0010MA
- Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03856697Written as Abivertinib Maleate Capsules
- Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCStatus unknownPhase 2Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03300115Written as AC0010
- A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIWithdrawnPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03058094Written as AC0010
- Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 TreatmentCompletedPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03053219Written as AC0010
- A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03060850Written as AC0010MA
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLCCompletedPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03001609Written as AC0010
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownPhase 1/2Sun Yat-sen UniversityNCT02274337Written as AC0010
Codes
What other systems call abivertinib · ClinicalTrials.gg INT001074
- MeSH (NLM) C000630672abivertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CER0OPG92LABIVERTINIBConfirmed FDA, NLM
- NCI Thesaurus C147125AbivertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630672 | abivertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CER0OPG92L | ABIVERTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C147125 | Abivertinib | One source FDA |
Also registered as abivertinib maleate (UNII Y50131AMFJ) and abivertinib maleate anhydrous (UNII 0447KM2XTD).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.